11/15
08:03 am
tars
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $36.00 to $41.00. They now have a "neutral" rating on the stock.
Low
Report
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $36.00 to $41.00. They now have a "neutral" rating on the stock.
11/14
08:23 am
tars
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) had its price target raised by analysts at Oppenheimer Holdings Inc. from $63.00 to $65.00. They now have an "outperform" rating on the stock.
Medium
Report
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) had its price target raised by analysts at Oppenheimer Holdings Inc. from $63.00 to $65.00. They now have an "outperform" rating on the stock.
11/14
02:31 am
tars
Tarsus Pharmaceuticals Inc (TARS) Q3 2024 Earnings Call Highlights: Record Sales and Strategic ... [Yahoo! Finance]
Medium
Report
Tarsus Pharmaceuticals Inc (TARS) Q3 2024 Earnings Call Highlights: Record Sales and Strategic ... [Yahoo! Finance]
11/13
04:05 pm
tars
Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements
Low
Report
Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements
11/13
08:44 am
tars
Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors [Yahoo! Finance]
Low
Report
Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors [Yahoo! Finance]
11/13
08:30 am
tars
Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors
Low
Report
Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors
11/7
11:31 am
tars
Tarsus Pharmaceuticals, Inc. (TARS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? [Yahoo! Finance]
Low
Report
Tarsus Pharmaceuticals, Inc. (TARS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? [Yahoo! Finance]
11/6
04:30 pm
tars
Tarsus to Report Third Quarter 2024 Financial Results on Wednesday, November 13, 2024
Low
Report
Tarsus to Report Third Quarter 2024 Financial Results on Wednesday, November 13, 2024
11/5
08:30 am
tars
Tarsus Appoints Elizabeth Yeu, M.D., as Chief Medical Officer
Medium
Report
Tarsus Appoints Elizabeth Yeu, M.D., as Chief Medical Officer
10/17
08:30 am
tars
Tarsus Launches “Your Mitey Problem,” the First Direct-to-Consumer TV Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25%
Low
Report
Tarsus Launches “Your Mitey Problem,” the First Direct-to-Consumer TV Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25%
9/25
05:00 pm
tars
Tarsus to Participate in Fireside Chat at UBS Virtual Ophthalmology Day 2024
Low
Report
Tarsus to Participate in Fireside Chat at UBS Virtual Ophthalmology Day 2024
9/6
07:00 am
tars
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) was upgraded by analysts at William Blair to a "strong-buy" rating.
High
Report
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) was upgraded by analysts at William Blair to a "strong-buy" rating.
8/28
05:00 pm
tars
Tarsus to Participate in Fireside Chat at the 2024 Wells Fargo Securities Healthcare Conference
Low
Report
Tarsus to Participate in Fireside Chat at the 2024 Wells Fargo Securities Healthcare Conference